People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bright Peak Therapeutics, Inc. | — | Pharma | Series D+ | $196.5M | $1.0B | 2024 |
Jon Wigginton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jon Wigginton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Josh Resnick | 1 | 7 |
| Laura Shawver | 1 | 6 |
| Alexander Mayweg | 1 | 4 |
| Christine Siu | 1 | 2 |
| Tom Woiwode | 1 | 2 |
| EMILY MINKOW | 1 | 2 |
| Jacob Chacko | 1 | 2 |
| Vijaya Pattabiraman | 1 | 1 |
| Fredrik Wiklund | 1 | 1 |
| Bertolt Kreft | 1 | 1 |
| Michael Rosenzweig | 1 | 1 |
| Matthew Robbins | 1 | 1 |
| Leena Gandhi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.